The company is a high-tech biopharmaceutical listed company. We only develop innovative drugs with significant technical advantages or market advantages (including traditional Chinese medicines or natural medicines, stem cell drugs) or products and new medical devices with similar medicinal functions, and independently develop, invest, or acquire technologies, products, or enterprises that meet these standards, and have a market position that includes but is not limited to patent protection. This is the company's basic product development strategy. The company is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of allergic disease diagnosis and treatment products. It has a leading position in the desensitization treatment market in China, and is gradually promoting research and development work in other fields such as stem cells and natural medicines (anti-drug resistant antibiotics). Drugs approved by the company for marketing in China include dust mite drops, artemisia artemisia pollen allergen sublingual drops, dust mite skin prick diagnostic kit, house dust mite skin prick diagnostic kit, artemisia artemisia pollen allergen skin prick solution, white birch pollen allergen skin prick solution, and Humulus pollen allergen skin prick solution. The company has received honors such as National High-tech Enterprise, Deqing County's “Top Ten” Enterprise Science and Technology Workers, Huzhou City's “365” Outstanding Innovation Team, and the Deqing County Government Quality Award.
No Data